Testing combination therapy before surgery for liver cancer

Plain-English translation of NCT07801287 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated September 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new combination treatment for intermediate-stage liver cancer in patients who might be candidates for surgery. The treatment combines two immunotherapy medications called iparomlimab and tuvonralimab, along with a type of radiation therapy called stereotactic body radiation therapy (SBRT) and a medication called lenvatinib. The goal is to see if giving this combination before surgery can improve outcomes and survival for people with this type of cancer.

Many people with intermediate-stage liver cancer need better treatment options before surgery. Researchers believe that combining immunotherapy (which helps your immune system fight cancer), targeted radiation, and a drug that slows cancer growth might work better together than any single approach alone.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with intermediate-stage hepatocellular carcinoma that doctors believe can be surgically removed
you have not received any prior cancer treatment
you are in generally good health with normal organ and bone marrow function
you have a good performance status (able to carry out daily activities with minimal limitations)

You likely don't qualify if…

you have received previous cancer treatment for any condition
cancer has spread outside your liver to other parts of your body
you have had a liver transplant or are planning to have one
you have active autoimmune disease or a recent history of serious autoimmune conditions
you have bleeding problems, severe heart or lung disease, or other serious medical conditions that the study doctor thinks would make participation unsafe

What participation looks like

You would receive the immunotherapy medication combination along with lenvatinib as a pill before undergoing radiation therapy sessions. The treatment is designed to shrink your tumor before surgery, which is scheduled as part of your care plan. You'll have regular medical visits and imaging scans to monitor how well the treatment is working and to watch for any side effects. The trial is small, enrolling about 20 people total, and takes place at a single cancer center.

AI-generated summary from trial data · Sep 11, 2026 · Not medical advice

Trial locations(1 site)

China

Tianjin medical university institute & hospital, Tianjin